Cargando…

Post-exposure prophylaxis with SA58 (anti-SARS-COV-2 monoclonal antibody) nasal spray for the prevention of symptomatic COVID-19 in healthy adult workers: a randomized, single-blind, placebo-controlled clinical study*

Monoclonal antibodies (mAbs) and the post-exposure prophylaxis (PEP) with mAbs represent a very important public health strategy against coronavirus disease 2019 (COVID-19). This study has assessed a new Anti-SARS-COV-2 mAb (SA58) Nasal Spray for PEP against COVID-19 in healthy adults aged 18 years...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Rui, Zeng, Gang, Yu, Jianxing, Meng, Xing, Chen, Xiaoyou, Li, Jing, Xie, Xiaoliang, Lian, Xiaojuan, Zhang, Zhiyun, Cao, Yunlong, Yin, Weidong, Jin, Ronghua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	Coronaviruses
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10215016/ https://www.ncbi.nlm.nih.gov/pubmed/37157134 http://dx.doi.org/10.1080/22221751.2023.2212806

Ejemplares similares

Safety and Effectiveness of SA58 Nasal Spray Against COVID-19 Infection in Medical Personnel: An Open-Label, Blank-Controlled Study — Hohhot City, Inner Mongolia Autonomous Region, China, 2022
por: Si, Shujie, et al.
Publicado: (2023)

A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses
por: Wang, Pengfei, et al.
Publicado: (2021)

Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccination
por: Wang, Meiyu, et al.
Publicado: (2021)

SARS-CoV-2 hijacks neutralizing dimeric IgA for nasal infection and injury in Syrian hamsters(1)
por: Zhou, Biao, et al.
Publicado: (2023)

A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants
por: Lam, Joy-Yan, et al.
Publicado: (2022)

Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial
por: Wang, Xuan-Yi, et al.
Publicado: (2022)

Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern in real-world: a literature review and meta-analysis
por: Shao, Weihao, et al.
Publicado: (2022)

COVID-19 vaccination in people living with HIV and AIDS (PLWHA) in China: A cross-sectional study
por: Lv, Xuan, et al.
Publicado: (2023)

Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants
por: Zhao, Zhuxiang, et al.
Publicado: (2022)

The impact of COVID-19 pandemic on rabies post-exposure prophylaxis services in Asia
por: Gongal, Gyanendra, et al.
Publicado: (2022)

SARS-CoV-2 IgG seropositivity after the severe Omicron wave of COVID-19 in Hong Kong
por: Poon, Rosana Wing-Shan, et al.
Publicado: (2022)

A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques
por: Li, Yuzhong, et al.
Publicado: (2021)

The interplay between emerging human coronavirus infections and autophagy
por: Zhao, Zhenyu, et al.
Publicado: (2021)

Fast inactivation of SARS-CoV-2 by UV-C and ozone exposure on different materials
por: Criscuolo, Elena, et al.
Publicado: (2021)

COVID-19-associated cytokine storm syndrome and diagnostic principles: an old and new Issue
por: Yongzhi, Xi
Publicado: (2021)

Isolation of SARS-CoV-2 strains carrying a nucleotide mutation, leading to a stop codon in the ORF 6 protein
por: Delbue, Serena, et al.
Publicado: (2021)

Saliva viral load better correlates with clinical and immunological profiles in children with coronavirus disease 2019
por: Chua, Gilbert T., et al.
Publicado: (2021)

Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection
por: Ye, Zi-Wei, et al.
Publicado: (2021)

The in vitro antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor
por: Hu, Yanmei, et al.
Publicado: (2021)

Novel dual multiplex real-time RT-PCR assays for the rapid detection of SARS-CoV-2, influenza A/B, and respiratory syncytial virus using the BD MAX open system
por: Chung, Hsing-Yi, et al.
Publicado: (2021)

Susceptibility of rabbits to SARS-CoV-2
por: Mykytyn, Anna Z., et al.
Publicado: (2021)

Critical role of neutralizing antibody for SARS-CoV-2 reinfection and transmission
por: Kim, Young-Il, et al.
Publicado: (2021)

A household case evidences shorter shedding of SARS-CoV-2 in naturally infected cats compared to their human owners
por: Neira, Víctor, et al.
Publicado: (2021)

Enhanced replication fitness of MERS-CoV clade B over clade A strains in camelids explains the dominance of clade B strains in the Arabian Peninsula
por: Te, Nigeer, et al.
Publicado: (2021)

Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in golden Syrian hamster
por: Brustolin, Marco, et al.
Publicado: (2021)

Sequential infections with rhinovirus and influenza modulate the replicative capacity of SARS-CoV-2 in the upper respiratory tract
por: Essaidi-Laziosi, Manel, et al.
Publicado: (2022)

Direct neuronal infection of SARS-CoV-2 reveals cellular and molecular pathology of chemosensory impairment of COVID-19 patients
por: Lyoo, Kwang-Soo, et al.
Publicado: (2022)

Safety, mucosal and systemic immunopotency of an aerosolized adenovirus-vectored vaccine against SARS-CoV-2 in rhesus macaques
por: Xu, Fang, et al.
Publicado: (2022)

Resistance of SARS-CoV-2 Omicron variant to convalescent and CoronaVac vaccine plasma
por: Wang, Yingdan, et al.
Publicado: (2022)

A new testing platform using fingerstick blood for quantitative antibody response evaluation after SARS-CoV-2 vaccination
por: Du, Jinwei, et al.
Publicado: (2022)

Preclinical immunological evaluation of an intradermal heterologous vaccine against SARS-CoV-2 variants
por: Fan, Shengtao, et al.
Publicado: (2022)

Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost
por: Ai, Jingwen, et al.
Publicado: (2022)

Obatoclax inhibits SARS-CoV-2 entry by altered endosomal acidification and impaired cathepsin and furin activity in vitro
por: Mao, Binli, et al.
Publicado: (2022)

Omicron variant susceptibility to neutralizing antibodies induced in children by natural SARS-CoV-2 infection or COVID-19 vaccine
por: Chen, Lin-Lei, et al.
Publicado: (2022)

Etesevimab in combination with JS026 neutralizing SARS-CoV-2 and its variants
por: Wang, Fengze, et al.
Publicado: (2022)

Possible recombination between two variants of concern in a COVID-19 patient
por: He, Yaqing, et al.
Publicado: (2022)

Genetic analysis of a SARS-CoV-2 Omicron variant from a Chinese traveller returning from overseas
por: Jia, Hongling, et al.
Publicado: (2022)

A new screening system for entry inhibitors based on cell-to-cell transmitted syncytia formation mediated by self-propagating hybrid VEEV-SARS-CoV-2 replicon
por: Li, Na, et al.
Publicado: (2022)

B cell receptor signatures associated with strong and poor SARS-CoV-2 vaccine responses
por: Lin, Ke, et al.
Publicado: (2022)

Drastic decline in sera neutralization against SARS-CoV-2 Omicron variant in Wuhan COVID-19 convalescents
por: Ma, Chengbao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_26jullo8sb6an91lf9sj71qb17